2023
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226. Journal Of Clinical Oncology 2023, 41: 1076-1076. DOI: 10.1200/jco.2023.41.16_suppl.1076.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast cancerThymidine kinase 1 activityHormone receptor-positive metastatic breast cancerPositive metastatic breast cancerOverall survivalEndocrine therapyCA 15Breast cancerCA15-3Predictors of PFSFirst-line endocrine therapySubsequent progression-free survivalWorse progression-free survivalSerum thymidine kinase 1Systemic endocrine therapyMultivariable Cox modelCox regression analysisWorse overall survivalHypothesis-generating dataCycles of treatmentTamoxifen useSystemic therapySerum levelsMultivariable analysis
2021
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionSerum insulin levelsCancer survivorsLoss interventionPercent body fatSerum levelsSerum biomarkersTissue biomarkersBody compositionMonth 6Insulin levelsBreast tissueBreast cancerInsulin receptorBody fatStage I breast cancerBreast tissue levelsI breast cancerWeight loss trialBreast tissue markersLevels of CD163Breast tissue biopsiesUsual careLifestyle intervention
2012
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research And Treatment 2012, 137: 631-636. PMID: 23242617, PMCID: PMC3867793, DOI: 10.1007/s10549-012-2374-0.Peer-Reviewed Original ResearchConceptsBreast cancerBone metastasesStage IP1NP levelsSerum levelsIL-6Procollagen type I N-terminal propeptideType I N-terminal propeptideCox proportional hazards regression analysisProportional hazards regression analysisEarly-stage breast cancerPoor OS rateSerum P1NP levelsKaplan-Meier methodOverall survival rateHazards regression analysisLower overall survivalBone metastasis developmentBreast cancer metastasisBlood sample collectionN-terminal propeptideAdvanced diseaseOverall survivalOS ratesSerum P1NPEvaluation of circulating biomarkers of bone metastases in early-stage breast cancer.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10-10. DOI: 10.1200/jco.2012.30.30_suppl.10.Peer-Reviewed Original ResearchP1NP levelsBreast cancerStage IInterleukin-6Cox proportional hazards regression analysisStage IV breast cancerElecsys 2010Proportional hazards regression analysisKaplan-Meier methodTime of diagnosisHazards regression analysisWorse overall survivalBone metastasis developmentProcollagen type 1Breast cancer recurrenceRoche Elecsys 2010Advanced diseaseMetastatic diseaseOverall survivalBone metastasesClinical factorsSerum levelsSerum P1NPBone turnoverBiomarker levelsEvaluation of circulating biomarkers of bone metastasis in early-stage breast cancer.
Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10613-10613. DOI: 10.1200/jco.2012.30.15_suppl.10613.Peer-Reviewed Original ResearchP1NP valuesInterleukin-6Breast cancerClinical factorsHazard ratioCox proportional hazards regression analysisCox proportional hazards regression modelElecsys 2010Proportional hazards regression analysisEarly-stage breast cancerProportional hazards regression modelsSerum P1NP levelsKaplan-Meier methodHazards regression analysisBone metastasis developmentHazards regression modelsProcollagen type 1Breast cancer recurrenceRoche Elecsys 2010Advanced diseaseP1NP levelsBone metastasesSerum levelsBone turnoverUnivariate analysis
2008
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. British Journal Of Cancer 2008, 99: 68-71. PMID: 18560403, PMCID: PMC2453019, DOI: 10.1038/sj.bjc.6604443.Peer-Reviewed Original ResearchConceptsCollagen IV levelsHealthy womenCancer patientsBreast cancerPreoperative chemotherapySerum levelsCollagen IVBaseline serum levelsSerum collagen IVPrimary breast cancerBreast cancer patientsSera of patientsMarkers of angiogenesisSandwich enzyme-linked immunoassayEnzyme-linked immunoassayCollagen IV concentrationVascular basement membraneClinical stageHER2 statusHealthy controlsSignificant further increaseHealthy volunteersPatientsChemotherapyStage II